368 related articles for article (PubMed ID: 29063289)
1. Salsolinol: an Unintelligible and Double-Faced Molecule-Lessons Learned from In Vivo and In Vitro Experiments.
Kurnik-Łucka M; Panula P; Bugajski A; Gil K
Neurotox Res; 2018 Feb; 33(2):485-514. PubMed ID: 29063289
[TBL] [Abstract][Full Text] [Related]
2. Isolation and Sequencing of Salsolinol Synthase, an Enzyme Catalyzing Salsolinol Biosynthesis.
Chen X; Zheng X; Ali S; Guo M; Zhong R; Chen Z; Zhang Y; Qing H; Deng Y
ACS Chem Neurosci; 2018 Jun; 9(6):1388-1398. PubMed ID: 29602279
[TBL] [Abstract][Full Text] [Related]
3. [Salsolinol, an endogenous molecule. Possible implications in alcoholism, Parkinson's disease and pain].
Vernay D; Eschalier A; Durif F; Aumaitre O; Rigal B; Ben Sadoun A; Fialip J; Marty H; Philip E; Bougerolle AM
Encephale; 1989; 15(6):511-6. PubMed ID: 2515055
[TBL] [Abstract][Full Text] [Related]
4. Dopamine-derived 1-methyl-6,7-dihydroxyisoquinolines as hydroxyl radical promoters and scavengers in the rat brain: in vivo and in vitro studies.
Maruyama W; Dostert P; Naoi M
J Neurochem; 1995 Jun; 64(6):2635-43. PubMed ID: 7760044
[TBL] [Abstract][Full Text] [Related]
5. Neurochemical changes induced by acute and chronic administration of 1,2,3,4-tetrahydroisoquinoline and salsolinol in dopaminergic structures of rat brain.
Antkiewicz-Michaluk L; Romañska I; Papla I; Michaluk J; Bakalarz M; Vetulani J; Krygowska-Wajs A; Szczudlik A
Neuroscience; 2000; 96(1):59-64. PubMed ID: 10683410
[TBL] [Abstract][Full Text] [Related]
6. Dopamine-derived endogenous 1(R),2(N)-dimethyl-6,7-dihydroxy- 1,2,3,4-tetrahydroisoquinoline, N-methyl-(R)-salsolinol, induced parkinsonism in rat: biochemical, pathological and behavioral studies.
Naoi M; Maruyama W; Dostert P; Hashizume Y; Nakahara D; Takahashi T; Ota M
Brain Res; 1996 Feb; 709(2):285-95. PubMed ID: 8833765
[TBL] [Abstract][Full Text] [Related]
7. Chronic salsolinol administration prevents the behavioral and neurochemical effects of L-DOPA in rats.
Wąsik A; Romańska I; Michaluk J; Antkiewicz-Michaluk L
Neurotox Res; 2015 May; 27(4):399-410. PubMed ID: 25711629
[TBL] [Abstract][Full Text] [Related]
8. Dopamine-derived salsolinol derivatives as endogenous monoamine oxidase inhibitors: occurrence, metabolism and function in human brains.
Naoi M; Maruyama W; Nagy GM
Neurotoxicology; 2004 Jan; 25(1-2):193-204. PubMed ID: 14697894
[TBL] [Abstract][Full Text] [Related]
9. Antidopaminergic effects of 1,2,3,4-tetrahydroisoquinoline and salsolinol.
Antkiewicz-Michaluk L; Michaluk J; Romańska I; Papla I; Vetulani J
J Neural Transm (Vienna); 2000; 107(8-9):1009-19. PubMed ID: 11041279
[TBL] [Abstract][Full Text] [Related]
10. The Mechanism of Action of Salsolinol in Brain: Implications in Parkinson's Disease.
Voon SM; Ng KY; Chye SM; Ling APK; Voon KGL; Yap YJ; Koh RY
CNS Neurol Disord Drug Targets; 2020; 19(10):725-740. PubMed ID: 32881676
[TBL] [Abstract][Full Text] [Related]
11. Salsolinol, a dopamine-derived tetrahydroisoquinoline, induces cell death by causing oxidative stress in dopaminergic SH-SY5Y cells, and the said effect is attenuated by metallothionein.
Wanpen S; Govitrapong P; Shavali S; Sangchot P; Ebadi M
Brain Res; 2004 Apr; 1005(1-2):67-76. PubMed ID: 15044066
[TBL] [Abstract][Full Text] [Related]
12. Salsolinol, a derivate of dopamine, is a possible modulator of catecholaminergic transmission: a review of recent developments.
Mravec B
Physiol Res; 2006; 55(4):353-364. PubMed ID: 16238467
[TBL] [Abstract][Full Text] [Related]
13. A novel enzyme enantio-selectively synthesizes (R)salsolinol, a precursor of a dopaminergic neurotoxin, N-methyl(R)salsolinol.
Naoi M; Maruyama W; Dostert P; Kohda K; Kaiya T
Neurosci Lett; 1996 Jul; 212(3):183-6. PubMed ID: 8843103
[TBL] [Abstract][Full Text] [Related]
14. Salsolinol, a tetrahydroisoquinoline catechol neurotoxin, induces human Cu,Zn-superoxidie dismutase modificaiton.
Kang JH
J Biochem Mol Biol; 2007 Sep; 40(5):684-9. PubMed ID: 17927901
[TBL] [Abstract][Full Text] [Related]
15. Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease.
Moser A; Siebecker F; Vieregge P; Jaskowski P; Kömpf D
J Neural Transm (Vienna); 1996; 103(4):421-32. PubMed ID: 9617786
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of tyrosine hydroxylase by R and S enantiomers of salsolinol, 1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline.
Minami M; Takahashi T; Maruyama W; Takahashi A; Dostert P; Nagatsu T; Naoi M
J Neurochem; 1992 Jun; 58(6):2097-101. PubMed ID: 1349343
[TBL] [Abstract][Full Text] [Related]
17. Absence of a role for salsolinol in the mechanism of ethanol teratogenicity.
Nesterick CA; Rahwan RG
Dev Pharmacol Ther; 1981; 3(2):99-107. PubMed ID: 7198572
[TBL] [Abstract][Full Text] [Related]
18. Stereospecific occurrence of a parkinsonism-inducing catechol isoquinoline, N-methyl(R)salsolinol, in the human intraventricular fluid.
Maruyama W; Narabayashi H; Dostert P; Naoi M
J Neural Transm (Vienna); 1996; 103(8-9):1069-76. PubMed ID: 9013394
[TBL] [Abstract][Full Text] [Related]
19. Interrelationship between activation of dopaminergic pathways and cerebrospinal fluid concentration of dopamine tetrahydroisoquinoline metabolite salsolinol in humans: preliminary findings.
Faraj BA; Camp VM; Kutner M
Alcohol Clin Exp Res; 1991 Feb; 15(1):86-9. PubMed ID: 2024737
[TBL] [Abstract][Full Text] [Related]
20. [Salsolinol, 3-O-methyl-dopa and homovanillic acid in the cerebrospinal fluid of Parkinson patients].
Krygowska-Wajs A; Szczudlik A; Antkiewicz-Michaluk L; Romańska I; Vetulani J
Neurol Neurochir Pol; 1997; 31(5):875-85. PubMed ID: 9513952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
